FDA Issues Approvable Letter For Ceftobiprole For Treatment Of Complicated Skin Infections

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced that it received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. J&JPRD, along with its co-development partner, Swiss-based Basilea Pharmaceutica Ltd.

More: continued here

Filed under: Dermatology on April 2nd, 2008